Burney Co. reduced its stake in Bristol-Myers Squibb (NYSE:BMY) by 7.2% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,553 shares of the biopharmaceutical company’s stock after selling 1,049 shares during the period. Burney Co.’s holdings in Bristol-Myers Squibb were worth $857,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in Bristol-Myers Squibb by 5.0% during the fourth quarter. BlackRock Inc. now owns 104,293,294 shares of the biopharmaceutical company’s stock worth $6,391,093,000 after acquiring an additional 4,945,515 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Bristol-Myers Squibb by 4.4% during the fourth quarter. Geode Capital Management LLC now owns 18,583,469 shares of the biopharmaceutical company’s stock worth $1,136,568,000 after acquiring an additional 777,929 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Bristol-Myers Squibb by 31.9% during the fourth quarter. Renaissance Technologies LLC now owns 14,302,900 shares of the biopharmaceutical company’s stock worth $876,482,000 after acquiring an additional 3,456,300 shares in the last quarter. TIAA CREF Investment Management LLC lifted its holdings in Bristol-Myers Squibb by 30.8% during the fourth quarter. TIAA CREF Investment Management LLC now owns 10,932,722 shares of the biopharmaceutical company’s stock worth $669,957,000 after acquiring an additional 2,573,967 shares in the last quarter. Finally, Legal & General Group Plc lifted its holdings in Bristol-Myers Squibb by 2.3% during the third quarter. Legal & General Group Plc now owns 8,622,652 shares of the biopharmaceutical company’s stock worth $549,588,000 after acquiring an additional 191,304 shares in the last quarter. Institutional investors and hedge funds own 71.49% of the company’s stock.
BMY opened at $52.74 on Friday. Bristol-Myers Squibb has a 1 year low of $52.16 and a 1 year high of $52.61. The stock has a market capitalization of $85.49 billion, a price-to-earnings ratio of 17.52, a PEG ratio of 1.31 and a beta of 0.99. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.39 and a current ratio of 1.52.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. The firm had revenue of $5.19 billion for the quarter, compared to the consensus estimate of $5.25 billion. During the same quarter last year, the business posted $0.84 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. analysts expect that Bristol-Myers Squibb will post 3.41 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th were paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 3.03%. The ex-dividend date was Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is 53.16%.
Several research firms have weighed in on BMY. ValuEngine lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Barclays reduced their target price on Bristol-Myers Squibb from $65.00 to $55.00 and set an “equal weight” rating on the stock in a report on Friday, April 27th. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, April 26th. Jefferies Group reiterated a “hold” rating and set a $66.00 target price on shares of Bristol-Myers Squibb in a report on Friday, April 13th. Finally, Vetr upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 target price on the stock in a report on Thursday, February 1st. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $63.68.
In other news, Director Dinesh C. Paliwal purchased 4,770 shares of the company’s stock in a transaction on Monday, April 30th. The shares were purchased at an average price of $52.40 per share, with a total value of $249,948.00. Following the purchase, the director now directly owns 8,027 shares of the company’s stock, valued at approximately $420,614.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.23% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.